This trial is designed to investigate the efficacy and safety of patients with locally advanced pancreatic cancer by SBRT combined with Zimberelimab(GLS-010).
18-75 years old.
Locally advanced pancreatic cancer confirmed histologically and defined according to the NCCN Pancreatic Cancer Guidelines v1.2022 as unresectable or surgically declined.
Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
The expected survival ≥ 3 months.
Tumor invasion of the gastrointestinal tract, specifically pancreatic tumor or lymph node metastasis invading the gastrointestinal parenchyma.
Woman who are pregnant or breastfeeding.
Has a known additional malignancy within the past 5 years, except for cured skin cancer and cervical carcinoma in situ.
Patients who have received prior treatment with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4, or with an agent directed to another stimulatory or co-inhibitory T-cell receptor.